Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Life Sciences Industry Analysis

UpdatedJun 30, 2026
DataAggregated Company Financials
Companies66
  • 7D9.8%
  • 3M12.9%
  • 1Y17.2%
  • YTD-7.4%

The Life Sciences industry is up 9.8% in the last week, with Thermo Fisher Scientific up 9.1%. Meanwhile, Nautilus Biotechnology actually underperformed within the industry, shrinking 23% in the last week. In the last 12 months, the industry was up 17%. Earnings are forecast to grow by 17% annually.

Industry Valuation and Performance

Has the U.S. Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 01 Jul 2026US$636.5bUS$151.2bUS$13.6b44.3x46.7x4.2x
Fri, 29 May 2026US$550.4bUS$150.6bUS$13.8b38.1x40x3.7x
Sun, 26 Apr 2026US$546.2bUS$149.0bUS$14.4b30.5x38x3.7x
Tue, 24 Mar 2026US$542.7bUS$147.8bUS$14.0b35.2x38.7x3.7x
Thu, 19 Feb 2026US$581.2bUS$147.7bUS$13.9b34.3x41.8x3.9x
Sat, 17 Jan 2026US$704.2bUS$145.8bUS$12.4b36.8x57x4.8x
Mon, 15 Dec 2025US$656.7bUS$145.8bUS$12.5b34.4x52.6x4.5x
Wed, 12 Nov 2025US$641.2bUS$145.7bUS$12.2b35.4x52.8x4.4x
Fri, 10 Oct 2025US$622.9bUS$144.3bUS$14.6b32.6x42.8x4.3x
Sun, 07 Sep 2025US$576.5bUS$144.3bUS$14.6b29.9x39.6x4x
Tue, 05 Aug 2025US$552.8bUS$144.0bUS$13.0b32.1x42.4x3.8x
Thu, 03 Jul 2025US$541.5bUS$142.9bUS$9.1b36.3x59.3x3.8x
Sat, 31 May 2025US$507.5bUS$142.9bUS$9.2b32.4x54.9x3.6x
Mon, 28 Apr 2025US$519.3bUS$142.5bUS$10.0b37.5x52x3.6x
Wed, 26 Mar 2025US$601.4bUS$143.0bUS$9.9b38.9x60.8x4.2x
Fri, 21 Feb 2025US$620.2bUS$143.3bUS$9.6b38.4x64.4x4.3x
Sun, 19 Jan 2025US$681.4bUS$142.4bUS$10.2b43.8x66.8x4.8x
Tue, 17 Dec 2024US$666.2bUS$142.4bUS$10.2b45.5x65.2x4.7x
Thu, 14 Nov 2024US$683.4bUS$142.4bUS$10.3b45x66.4x4.8x
Sat, 12 Oct 2024US$724.1bUS$141.8bUS$8.5b37.7x85.3x5.1x
Mon, 09 Sep 2024US$731.3bUS$141.8bUS$8.5b37.5x86.1x5.2x
Wed, 07 Aug 2024US$722.7bUS$141.0bUS$11.3b36.7x64.2x5.1x
Fri, 05 Jul 2024US$662.1bUS$141.3bUS$12.2b38.5x54.4x4.7x
Sun, 02 Jun 2024US$702.1bUS$141.3bUS$12.4b38.2x56.5x5x
Tue, 30 Apr 2024US$709.6bUS$141.6bUS$12.7b39.6x55.8x5x
Thu, 28 Mar 2024US$742.5bUS$142.1bUS$12.8b43.9x58x5.2x
Sat, 24 Feb 2024US$729.7bUS$142.1bUS$12.4b43.7x58.8x5.1x
Mon, 22 Jan 2024US$691.1bUS$153.8bUS$14.2b35.9x48.8x4.5x
Wed, 20 Dec 2023US$697.4bUS$153.8bUS$14.2b37.4x49x4.5x
Fri, 17 Nov 2023US$614.3bUS$153.9bUS$13.9b33.5x44.2x4x
Sun, 15 Oct 2023US$629.3bUS$154.6bUS$11.2b33.2x56.2x4.1x
Tue, 12 Sep 2023US$690.0bUS$154.6bUS$11.2b32.2x61.6x4.5x
Thu, 10 Aug 2023US$729.3bUS$154.6bUS$11.3b30.2x64.6x4.7x
Sat, 08 Jul 2023US$685.3bUS$152.4bUS$12.5b29.6x54.8x4.5x
Price to Earnings Ratio

54.8x


Total Market Cap: US$685.3bTotal Earnings: US$12.5bTotal Revenue: US$152.4bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Life Sciences Industry Price to Earnings3Y Average 56.1x202420252026
Current Industry PE
  • Investors are pessimistic on the American Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 46.7x which is lower than its 3-year average PE of 56.1x.
  • The industry is trading close to its 3-year average PS ratio of 4.4x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have grown 2.9% per year over the last three years, while revenues have remained mostly flat.
  • This means that companies overall are more efficiently conducting business since profits are increasing while sales have been flat.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market0.31%
Healthcare7.10%
Life Sciences9.76%
Clinical Research and Equipment9.76%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
TMO Thermo Fisher ScientificUS$501.366.8%
+US$11.9b		19.0%PE27.2x
DHR DanaherUS$190.486.4%
+US$8.1b		-5.3%PE36.7x
IQV IQVIA HoldingsUS$193.2212.8%
+US$3.7b		18.8%PE23.3x
MTD Mettler-Toledo InternationalUS$1.28k10.5%
+US$2.4b		6.0%PE29.5x
ICLR ICONUS$173.7121.8%
+US$2.4b		16.7%PE76.8x

Latest News

ATLN
US$0.92
Atlantic International
7D
-30.8%
1Y
-54.2%
LFCR
US$5.25
Lifecore Biomedical
7D
-7.2%
1Y
-34.0%
Analysis Article • 17h

Is Now An Opportune Moment To Examine Lifecore Biomedical, Inc. (NASDAQ:LFCR)?

Lifecore Biomedical, Inc. ( NASDAQ:LFCR ), is not the largest company out there, but it received a lot of attention...
DHR
US$190.48
Danaher
7D
6.4%
1Y
-5.3%
WAT
US$375.04
Waters
7D
5.0%
1Y
5.0%
MTD
US$1,277.51
Mettler-Toledo International
7D
10.5%
1Y
6.0%
IQV
US$193.22
IQVIA Holdings
7D
12.8%
1Y
18.8%
ICLR
US$173.71
ICON
7D
21.8%
1Y
16.7%
TMO
US$501.36
Thermo Fisher Scientific
7D
6.8%
1Y
19.0%
Seeking Alpha • Jun 29

Thermo Fisher Scientific: Gradually Getting Cheaper

Summary Thermo Fisher Scientific trades at 20-21x earnings, but organic growth remains modest and leverage is elevated. The recent $1.075B microbiology business sale was at a low 1.7x sales multiple and is dilutive to EPS. Thermo Fisher´s recent growth is largely M&A-driven, with net leverage at 3.5x and organic sales up only 1% in Q1 2026. Shares have stagnated since 2020 despite 50% revenue growth, as valuation multiples compress and organic momentum lags. Read the full article on Seeking Alpha
TECH
US$70.65
Bio-Techne
7D
25.6%
1Y
35.7%
SEER
US$1.66
Seer
7D
-4.0%
1Y
-24.2%
Narrative Update • Jun 22

SEER: Activist Bid And Buybacks Will Test Bullish Repricing Thesis

Analysts have raised their price target on Seer to $4.00, citing updated assumptions for higher revenue growth, a modestly higher discount rate, and a lower future P/E multiple as the key drivers of this revised view. What’s in the News for Seer Bradley L.
CRL
US$226.79
Charles River Laboratories International
7D
21.5%
1Y
46.9%
Analysis Article • Jun 21

Charles River Laboratories International (CRL) Stock Could Be 41% Undervalued After Lilly Tie Up And Upgrade

Charles River Laboratories International stock reacts to new AI drug discovery collaboration Charles River Laboratories International (CRL) is back in focus after a Morgan Stanley upgrade and a new collaboration with Eli Lilly's AI and machine learning drug discovery platform, TuneLab. See our latest analysis for Charles River Laboratories International. The recent Morgan Stanley upgrade and the Lilly TuneLab collaboration arrive as momentum in Charles River Laboratories International’s share...
VRXA
US$1.88
Veraxa Biotech
7D
-35.4%
1Y
-81.9%
CDT
US$0.56
CDT Equity
7D
-51.3%
1Y
-99.9%
CDXS
US$2.26
Codexis
7D
-5.4%
1Y
-5.8%
NAUT
US$1.87
Nautilus Biotechnology
7D
-19.7%
1Y
156.2%
CSBR
US$6.16
Champions Oncology
7D
-1.1%
1Y
-14.6%